

Example Client, XYZ123
1234 Warde Road
Ann Arbor MI 48108

EXAMPLE, REPORT W
WX0000003827 M 07/08/1978 45 Y

Referral Testing

Collected: 09/11/2023 13:51

Received: 09/11/2023 13:51

| <u>Test Name</u> | <u>Result</u> | <u>Flag</u> | <u>Ref-Ranges</u> | <u>Units</u> | <u>Site</u> |
|----------------------------|---------------|-------------|-------------------|--------------|-------------|
| Paliperidone, Serum/Plasma | 27 | | | ng/mL | NMRL |

Reporting Limit: 1.0 ng/mL

Synonym(s): Invega(R)

Paliperidone is an atypically-structured antipsychotic agent and the main pharmacologically active metabolite of Risperidone (commonly referred to as 9-hydroxyrisperidone).

The following mean plasma paliperidone concentrations have been reported:

3 mg single extended release oral dose:

4.9 ng/mL at 24 hours

6 mg single extended release oral dose:

10 ng/mL at 24 hours

12 mg single extended release oral dose:

20 ng/mL at 24 hours

3 mg extended release oral dose for 7 days:

11 ng/mL at 22 hours after last dose

78-156 mg IM once monthly for 6 months:

10-20 ng/mL (median trough concentration)

Acute ingestion of 180 and 504 mg extended release paliperidone resulted in serum concentrations of 170 and 883 ng/mL, respectively, approximately 40 hours after ingestion and the reported serum concentration following acute ingestion of 270 mg was 100 ng/mL 16 hours post-ingestion.

A femoral blood paliperidone concentration of 240 ng/mL was the only finding in an individual who died 2 weeks after a 525 depot IM injection.

The blood/plasma ratio of paliperidone is 0.7-0.8.

Analysis by High Performance Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

This test was developed and its performance characteristics determined by NMS Labs. It has not been cleared or approved by the US Food and Drug Administration.

Testing performed at NMS Labs, Inc.

200 Welsh Road

Horsham, PA 19044-2208

CLIA 39D0197898

Reported Date: 2023.09.11 13:51

LAB: L - LOW, H - HIGH, AB - ABNORMAL, C - CRITICAL, . - NOT TESTED

F311000021
WX0000003827

Printed D&T: 09/11/23 13:52

Ordered By: KAJAL SITWALA, MD, PhD
WX00000000002365

Kajal V. Sitwala, MD, PhD - Medical Director

Form: MM RL1

PAGE 1 OF 1